Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Moodys
McKinsey
Cantor Fitzgerald
Queensland Health
Fish and Richardson
Dow
Johnson and Johnson
US Army

Generated: May 21, 2018

DrugPatentWatch Database Preview

TAZICEF Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Tazicef patents expire, and what generic alternatives are available?

Tazicef is a drug marketed by Hospira and is included in two NDAs.

The generic ingredient in TAZICEF is ceftazidime. There are seventeen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the ceftazidime profile page.
Drug patent expirations by year for TAZICEF
Pharmacology for TAZICEF
Medical Subject Heading (MeSH) Categories for TAZICEF
Synonyms for TAZICEF
(6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-(1-carboxy-1-methyl-ethoxy)imino-acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
1-[[(6R,7R)-7-[[(2Z)-(2-AMINO-4-THIAZOLYL)[(1-CARBOXY-1-METHYLETHOXY)IMINO] ACETYL] AMINO]-2-CARBOXY-8-OXO-5-THIA-1-AZABICYCLO[4.2.0] OCT-2-EN-3-YL]METHYL]PYRIDINUM HYDROXIDE INNER SALT
1-{[(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}pyridin-1-ium
72558-82-8
78439-06-2
7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-(pyridinium-1-ylmethyl)-3,4-didehydrocepham-4-carboxylate
AB00513848
AB00513848-02
AB02837
AB1009357
AC1NUK7U
AK163513
AKOS015951273
AN-37419
BDBM50420259
BIDD:GT0734
C06889
C22H22N6O7S2
CAZ
Cefprozil, Antibiotic for Culture Media Use Only
Ceftazidim
ceftazidima
Ceftazidima [INN-Spanish]
ceftazidime
CEFTAZIDIME (ARGININE FORMULATION)
Ceftazidime (INN)
Ceftazidime (TN)
CEFTAZIDIME ACID
Ceftazidime anhydrous
Ceftazidime Sodium In Plastic Container
ceftazidimum
Ceftazidimum [INN-Latin]
Ceftazidine
Ceptaz
Ceptaz (TN)
CHEBI:3508
CHEMBL44354
CS-2810
D07654
DB00438
DTXSID5022770
Fortaz
Fortaz In Plastic Container
Fortum
GR 20263
HMS2090M13
HY-B0593
MolPort-006-137-763
Pentacef
Q-200811
SCHEMBL36849
SN 401
Tazidime
Tazidime In Plastic Container

US Patents and Regulatory Information for TAZICEF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira TAZICEF ceftazidime INJECTABLE;INJECTION 062662-002 Mar 6, 1986 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Hospira TAZICEF ceftazidime INJECTABLE;INJECTION 064032-002 Oct 31, 1993 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Hospira TAZICEF ceftazidime INJECTABLE;INJECTION 064032-001 Oct 31, 1993 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Hospira TAZICEF ceftazidime INJECTABLE;INJECTION 062662-003 Mar 6, 1986 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Federal Trade Commission
Harvard Business School
Moodys
US Army
Deloitte
Cantor Fitzgerald
QuintilesIMS
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.